Patent AT-E400268-T1: [Translated] BISINDOLYLMALEIMIDE FOR THE TREATMENT OF PROSTATE CANCER AND ACT-MEDIATED DISEASES
Description
The present invention provides a method of treating prostate cancer comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the formula (I) wherein R1 and R2 are each independently hydrogen or C1-C4 alkyl; or a pharmaceutically acceptable salt thereof. In a second embodiment, the invention provides a method of treating androgen-independent prostatic adenocarcinoma comprising administering to a patient in need thereof a therapeutically effective amount of compound of formula (I) or a pharmaceutically acceptable salt thereof. In a third embodiment, the invention provides a method of treating an AKT-mediated disease selected from the group consisting of glioblastoma, colon cancer, pancreatic cancer, ovarian cancer, endometrial cancer, and renal cell cancer, comprising administering to a patient in need thereof a therapeutically effective amount of compound of formula (I) or a pharmaceutically acceptable salt thereof.
Resources
| Name |
Format |
Description |
Link |
|
21 |
Access the complete Patent AT-E400268-T1: [Translated] BISINDOLYLMALEIMIDE FOR THE TREATMENT OF PROSTATE CANCER AND ACT-MEDIATED DISEASES on the official website. |
https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400268-T1 |
Tags
- patent
- chemistry
- research
- innovation
- pubchem